

IMPAX LABORATORIES INC
Form 8-K
January 12, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 12, 2016

Impax Laboratories, Inc.
(Exact name of registrant as specified in its charter)

Delaware **001-34263** **65-0403311**
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

30831 Huntwood Avenue, Hayward, CA 94544
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(510) 240-6000**

Not Applicable
(Former name or former address, if changed since last report)

Edgar Filing: IMPAX LABORATORIES INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On January 12, 2016, Impax Laboratories, Inc. (the “Company”) is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference. A copy of the materials that the Company will present at the conference is attached hereto as Exhibit 99.1 and incorporated herein by reference.

This Current Report on Form 8-K and the information in this Item 7.01 hereof will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor will it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act unless expressly identified therein as being specifically incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith.

Exhibit No.	Description
99.1	34th Annual J.P. Morgan Healthcare Conference Presentation dated as of January 12, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2016

IMPAX LABORATORIES, INC.

By: /s/ Bryan M. Reasons
Name: Bryan M. Reasons
Title: Senior Vice President,
Finance and
Chief Financial Officer

Exhibit No.	Description
99.1	34th Annual J.P. Morgan Healthcare Conference Presentation dated as of January 12, 2016.